The publication of successful Phase 3 trial results is a critical milestone for biotech companies, often leading to increased investor confidence and stock value. Given the high efficacy rate of 75% and the global need for effective malaria vaccines, this news is likely to be viewed positively by the market. However, the actual impact on the stock price will depend on broader market conditions, regulatory approvals, and Novavax's ability to commercialize the vaccine effectively.